jcp conference-coverage

Conference Coverage

Conference Coverage

Benefits and Challenges of the Enhancing Oncology Model

06/13/2023

At the ASCO 2023 Annual Meeting, Lalan Wilfong, MD, provided an overview of the Enhancing Oncology Model and how it differs from and improves upon the Oncology Care Model.

At the ASCO 2023 Annual Meeting,...

06/13/2023

Journal of Clinical Pathways

Conference Coverage

Research Shows that Health Care Costs Vary Based on HIC Status in Patients With NSCLC

06/13/2023

Emry Lloyd ;

In an abstract presented at ASCO 2023, researchers compared real-world data on health care costs for HIC-H and HIC-C patients with NSCLC before and after they received the HIC test.

In an abstract presented at ASCO...

06/13/2023

Journal of Clinical Pathways

Conference Coverage

Real-World Outcomes by Race in Patients with Chronic Lymphocytic Leukemia in the informCLL Registry Study

06/12/2023

Grace Taylor , MS, MA;

Data from the informCLL clinical trial, presented at the 2023 ASCO Annual Meeting, analyzed the impact of access to novel therapies on clinical outcomes stratified by race in patients with CLL/SLL.

Data from the informCLL clinical...

06/12/2023

Journal of Clinical Pathways

Conference Coverage

Impact of Race and Payor Status on Nephrectomy Procedure Type in Patients With Renal Cell Carcinoma

06/08/2023

In an interview with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting, Regina Barragán-Carrillo, MD, discusses her study on the influence of race and payor status on the treatment patterns of partial versus radical nephrectomy...

In an interview with the Journal...

06/08/2023

Journal of Clinical Pathways

Conference Coverage

Inequities in Next-Generation Sequencing Testing Among Patients With Advanced Non–Small Cell Lung Cancer

06/07/2023

Dr Gregory Vidal, Breast Medical Oncologist, West Cancer Center, Germantown, TN, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about his study on inequities in next-generation sequencing testing by race/ethnicity...

Dr Gregory Vidal, Breast Medical...

06/07/2023

Journal of Clinical Pathways

Conference Coverage

Analysis Finds That Commuting Distance Affects Equitable Access to and Enrollment in US Cancer Clinical Trials

06/05/2023

Emry Lloyd ;

In an abstract presented at ASCO 2023, researchers found that one-way commuting distance to US-based cancer trial sites is a key barrier to socioeconomically equitable clinical trial enrollment.

In an abstract presented at ASCO...

06/05/2023

Journal of Clinical Pathways

Conference Coverage

Case Studies of New Patient Access Programs at Two Cancer Centers

04/27/2023

Grace Taylor , MS, MA;

Kimberly Bell, RN, MBA, Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic, and Danielle McLaughlin, MPH, University of California San Diego, Moores Cancer Center, highlight different strategies...

Kimberly Bell, RN, MBA, Case...

04/27/2023

Journal of Clinical Pathways

Conference Coverage

Outcomes and Costs of Treatment for Patients With Metastatic Upper Tract Urothelial Carcinoma

03/31/2023

Grace Taylor , MS, MA;

At the 2023 ASCO GU Cancers Symposium, Daniel D Joyce, MD, and colleagues presented data on the outcomes and costs associated with the treatment of synchronous and metachronous metastatic upper tract urothelial carcinoma (mUTUC).

At the 2023 ASCO GU Cancers...

03/31/2023

Journal of Clinical Pathways

Videos

The Impact of Biosimilars on the Business of Oncology

03/28/2023

Andre Harvin, PharmD, MS, MBA, discusses controlling costs in the business of oncology through biosimilar use.

Andre Harvin, PharmD, MS, MBA,...

03/28/2023

Journal of Clinical Pathways

Videos

Barriers in Precision Medicine

03/24/2023

Sigrun Hallmeyer, MD, discusses the logistical challenges that health care workers encounter when treating patients with malignancies and employing precision medicine pathways, noting the impact that these challenges can have on a patient's...

Sigrun Hallmeyer, MD, discusses...

03/24/2023

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

2024 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Update: Impact on NSCLC Landscape

11/15/2024

The updated 2024 NCCN Guidelines® recommend broad genomic testing and the need for multidisciplinary care to accurately diagnose and treat non-small cell lung cancer. View this special report to learn more.

The updated 2024 NCCN...

11/15/2024

Journal of Clinical Pathways

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Conference Coverage

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products